A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/weilan-ye

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Weilan Ye

Staff Scientist, Molecular Oncology

Postdoc Mentor

"Time and again, Genentech is proven to be the industry leader. This is a place where creative minds have a good chance to transform medicine."

Years at Genentech

I came to Genentech as a postdoc in October 1995 to work on neural development and neural degenerative diseases. I enjoyed the dynamic and stimulating scientific environment so much that I decided to stay as a scientist. Beginning in November 1999, I started a small research lab focusing on vascular biology. Today, I am leading a multi-group program working on discovering potential treatments for a variety of diseases with vascular pathologies including exudative age related macular degeneration, diabetic retinopathy, hereditary vascular disorders, and cancer.

Postdoctoral Mentor

One of the most attractive and exciting features of being a scientist at Genentech is to mentor postdocs. Postdocs bring critical thinking, new ideas, and the youthful enthusiasm to our research programs. Mentoring postdocs energizes my mind and fuels my scientific curiosity. I truly enjoy helping them build their careers, and my group finds the postdocs an important part of our working “family”.

Featured Publication

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.

Dev Cell. 2016 Apr 18;37(2):114-25.

Ye W.

View Abstract

We are studying how vascular alteration contributes to human diseases. For example, increased vascular permeability is an important pathologic driver in the neovascular age-related macular degeneration and diabetic macular edema. Manipulating the molecular machineries that control vascular permeability may lead to the discovery of treatments for these diseases.

We are also exploring ways to modulate the vascular barrier function in order to increase or decrease leukocyte trafficking and drug distribution in disease tissues. Increasing lymphocyte trafficking into tumors, or decreasing leukocyte trafficking into inflamed tissues may be beneficial in managing these diseases.

University of Pittsburgh, Department of Biological Sciences, Ph.D. Molecular, Cellular, Developmental Biology Program – 1995
University of Science and Technology of China (USTC), Biophysics, B.S. – 1988

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Weilan Ye

Staff Scientist, Molecular Oncology

Featured Publication

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Weilan Ye

Staff Scientist, Molecular Oncology

Featured Publication

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.